Panel Urges Closer Scrutiny Of New Medical Technology

When the superficial attraction of the latest equipment outpaces our knowledge of its value, the results can be costly The United States government, concerned about increasing health care costs and unsure about the claims made about some recent technologies, is weighing a proposal that would ask federally funded researchers to prove that new machines are indeed better than their precursors before they become widely used. "The fact is, as technologies emerge, they are driven by those who intro

Written byJan Ziegler
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share


When the superficial attraction of the latest equipment outpaces our knowledge of its value, the results can be costly
The United States government, concerned about increasing health care costs and unsure about the claims made about some recent technologies, is weighing a proposal that would ask federally funded researchers to prove that new machines are indeed better than their precursors before they become widely used.

"The fact is, as technologies emerge, they are driven by those who introduce them - by industry," says Herbert Abrams, professor of radiology at Stanford University and chairman of an Institute of Medicine panel that issued a report late last year on the state of medical technology assessment. The report, "Assessment of Diagnostic Technology in Health Care," from the Council on Health Care Technology, found much to be upset about. Data collection for large-scale clinical studies may be slipshod or may not follow prescribed methodology, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies